Edition:
United States

Roche Holding AG (RHHBY.PK)

RHHBY.PK on OTC Markets Group

34.43USD
22 May 2017
Change (% chg)

-- (--)
Prev Close
$34.43
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,129,329
52-wk High
$36.82
52-wk Low
$25.25

Latest Key Developments (Source: Significant Developments)

U.S. FDA says expanded approved use of Subcutaneous Actemra to treat adults with Giant Cell Arteritis
Monday, 22 May 2017 10:42am EDT 

May 22 (Reuters) - U.S. FDA: :U.S. FDA says expanded the approved use of Subcutaneous Actemra (Tocilizumab) to treat adults with Giant Cell Arteritis.U.S. FDA says the FDA granted the supplemental approval of Actemra to Hoffman La Roche Inc.  Full Article

Cancer Genetics partners with Ventana Medical Systems for market access to predictive biomarker test
Monday, 15 May 2017 07:00am EDT 

May 15 (Reuters) - Cancer Genetics Inc :Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to ensure market access to predictive biomarker test for new immuno-oncology (io) therapy for advanced bladder cancer.Cancer Genetics - partnered with Ventana Medical Systems to enable rapid patient access to testing following FDA's approval of Roche's Ventana PD-l1 assay.  Full Article

Roche receives FDA approval for complementary pd-l1 biomarker test in Urothelial Carcinoma
Tuesday, 2 May 2017 03:52pm EDT 

May 2 (Reuters) - Roche Holding Ag :Roche receives FDA approval for Complementary PD-l1 (SP263) Biomarker test in Urothelial carcinoma.Continues to pursue regulatory approval for Ventana PD-l1 assay in other cancer indications in US and in other geographies.  Full Article

Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in Urothelial Carcinoma
Tuesday, 2 May 2017 03:36pm EDT 

May 2 (Reuters) - Roche Holding Ag : :Roche receives FDA approval for complementary PD-L1 (SP263) biomarker test in Urothelial Carcinoma.Continues to pursue regulatory approval for Ventana PD-L1 (SP263) assay in other cancer indications in US and in other geographies.  Full Article

Corvus Pharmaceuticals expands CPI-444 clinical collaboration with Genentech
Tuesday, 2 May 2017 08:30am EDT 

May 2 (Reuters) - Corvus Pharmaceuticals Inc : :Corvus Pharmaceuticals expands cpi-444 clinical collaboration with Genentech.Corvus Pharmaceuticals - Genentech will manage study operations for phase 1B/2 trial, which is expected to begin enrolling patients in second half of 2017.Corvus Pharmaceuticals Inc - financial terms were not disclosed.Corvus Pharmaceuticals Inc - Corvus will retain global development and commercialization rights to CPI-444.Corvus Pharmaceuticals Inc- expanded its clinical collaboration with Genentech, a member of Roche Group.Corvus Pharmaceuticals Inc- anticipated that randomized, controlled study will enroll up to 65 patients in treatment arm.  Full Article

Roche's O'Day says has seen no more thromboembolic events with ACE910
Thursday, 27 Apr 2017 09:36am EDT 

April 27 (Reuters) - Roche :Drugs head Dan O'Day says access limitations for multiple sclerosis medicine Ocrevus in United States 'are really none'.Says he is hopeful ACE910 will be available to hemophilia patients by end of 2017, early 2018.O'Day says has seen no more significant thromboembolic events with ACE910 beyond those already reported.Says Lucentis sales seen rising in FY2017, though pace may slow from 9 percent in first quarter.  Full Article

BD licenses molecular indexing technology to Roche
Wednesday, 26 Apr 2017 06:59am EDT 

April 26 (Reuters) - Becton Dickinson And Co ::Becton Dickinson And Co - has non-exclusively licensed its patented stochastic labelling technology to Roche for multiple commercial applications.Becton Dickinson And Co - specific financial terms of agreement have not been disclosed.  Full Article

Roche Holding says strategic alliance with Sentara
Wednesday, 19 Apr 2017 07:00am EDT 

April 19 (Reuters) - Roche Holding Ag ::Establishment of a strategic alliance with Sentara Consolidated Laboratories of Norfolk, VA.  Full Article

FDA grants Genentech’s tecentriq accelerated approval
Monday, 17 Apr 2017 09:15pm EDT 

April 17 (Reuters) - Roche Holding Ag ::FDA grants Genentech’s tecentriq (atezolizumab) accelerated approval as initial treatment for certain people with advanced bladder cancer.Genentech - "it is not known if tecentriq is safe and effective in children".  Full Article

Genentech says U.S. FDA approves Lucentis (ranibizumab injection) for diabetic retinopathy
Monday, 17 Apr 2017 01:13pm EDT 

April 17 (Reuters) - Genentech::FDA approves Genentech’s Lucentis (ranibizumab injection) for diabetic retinopathy, the leading cause of blindness among working age adults in the United States.FDA approved Lucentis 0.3 mg for monthly treatment of all forms of diabetic retinopathy.In analysis that supported approval, patients with/without DME in Lucentis group experienced improvements in severity of their retinopathy.  Full Article

More From Around the Web

UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients

May 17 Pivotal trial results for Merck & Co Inc's immunotherapy drug Keytruda show that it lengthened survival by three months, or nearly 40 percent, for patients with advanced bladder cancer who had stopped responding to chemotherapy.